Sentence examples for minor hypoglycaemia was from inspiring English sources

The incidence of minor hypoglycaemia was similar for both groups; however, incidence of minor hypoglycaemia was increased in patients using concomitant SU therapy compared to patients not using SU.

The rate of minor hypoglycaemia was significantly lower for each liraglutide group than for the glimepiride group (both p < 0.0001).

Minor hypoglycaemia was defined as self-reported transient symptoms of hypoglycaemia and a blood glucose <3 mmol (54 mg/dl).

Minor hypoglycaemia was defined as a blood glucose measurement <56 mg/dL (3.1 mmol/L) with or without symptoms.

The proportion of patients experiencing minor hypoglycaemia was similar in both the liraglutide and insulin glargine groups (27.4 vs. 28.9%).

The incidence of minor hypoglycaemia was similarly low in patients not using concomitant SU in ExQW and ExBID groups (Table 3).

The HbA1c at the end of the first year was 7.6, 7.3 and 7.2%, respectively; whilst rates of minor hypoglycaemia were 2.3, 5.7 and 12.0 events/year respectively (21).

In another 24-week study, liraglutide 0.9 mg once daily as add-on to sulfonylurea monotherapy reduced HbA1c by 1.6% (baseline 8.2%; placebo-subtracted: −1.3%) without causing any major hypoglycaemic episodes, although higher rates of minor hypoglycaemia were reported among subjects in the liraglutide group than in those on placebo [ 21].

The superior glycaemic control with the BIAsp 30 regimen was reflected in a higher incidence of minor hypoglycaemia (20% vs 9% of patients; p = 0.012), but major hypoglycaemia was very rare in both groups.

No major hypoglycaemia was observed during the study, and reported hypoglycaemia rates (including overall, nocturnal and minor hypoglycaemia) decreased in the total cohort and in both subgroups.

No major hypoglycaemia was observed.